Dr. Craig Thomas

 

Dr. Craig Thomas
Chemistry Technology

Craig Thomas received his BS from the University of Indianapolis in 1995 and received an MS degree and Ph.D. from Syracuse University in 2000. He then undertook a post-doctoral work in the laboratories of Dr. Sidney Hecht at the University of Virginia where he earned a fellowship through the American Cancer Society. From there, he moved the NIH where he directed the chemical biology core of the National Institute of Diabetes and Digestive and Kidney Diseases. In 2007, he moved to the NIH Chemical Genomics Center (currently the NIH Center for Advancing Translational Sciences) where he serves as the group leader of chemistry technologies.

Go to Craig's Page

 

 
Dr. Craig Thomas
Chemistry Technology
301-217-4079

Research Summary

For more information about Chemistry Technology at NCATS, please go to: http://www.ncats.nih.gov/research/reengineering/ncgc/chemtech/chem-tech.html

PublicationsPatents

1 - 5 of 104 results

1 2 3 4 5  ... 

1)  Jiang J, McCoy JG, Shen M, Leclair CA, Huang W, Negri A, Li J, Blue R, Harrington AW, Naini S, David G, Choi W, Volpi E, Fernandez J, Babayeva M, Nedelman MA, Filizola M, Coller BS, Thomas CJ.
A novel class of ion displacement ligands as antagonists of the aIIbß3 receptor that limit conformational reorganization of the receptor.
Bioorg. Med. Chem. Lett. 24: 1148-53, 2014. [Journal]
2)  Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM.
Blockade of oncogenic I?B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 111: 11365-70, 2014. [Journal]
3)  Vazquez-Ortiz G, Chisholm C, Xu X, Lahusen TJ, Li C, Sakamuru S, Huang R, Thomas CJ, Xia M, Deng C.
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
Breast Cancer Res. 16: R67, 2014. [Journal]
4)  Thomas CJ, McKew JC.
Editorial: Playing Well with Others! Initiating and Sustaining Successful Collaborations between Industry, Academia and Government.
Curr Top Med Chem. 14: 291-3, 2014. [Journal]
5)  Shukla S, Chufan EE, Singh S, Skoumbourdis AP, Kapoor K, Boxer MB, Duveau DY, Thomas CJ, Talele TT, Ambudkar SV.
Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein.
Leukemia. 28: 961-4, 2014. [Journal]

 

 

 

 

1 

1) Beutler JA, Chung S, Jiang JK, Legrice SF, Thomas CJ, Wilson JA (submitted in 2011) Tropolone Compounds For Treating Or Preventing Retroviral Infection.
Patent issued: 8,993,768 (US in 2015).
Patent pending: PCT/US2012/037208 (PC application).


2) FitzGerald D, Jiang JK, O'Shea JJ, Onda M, Pastan IH, Thomas CJ (submitted in 2010) Inhibition Of Antibody Responses To Foreign Proteins.
Patent pending: PCT/US2011/024382 (PC application).
Patent pending: PCT/US2011/024382 (PC application).

 

 

 

////////